The p53 tumor suppressor is frequently inactivated in tumors by point mutations in the DNA-binding domain, resulting in loss of sequence-specific DNA binding and transcription function. We present evidence that ellipticine can restore the transactivation function of several transfected p53 mutants (175 H, 248W, 249S, 273 H, 281G) , resulting in the induction of p53-responsive genes (p21
WAF1
,MDM2) and activation of a p53-responsive luciferase reporter. Ellipticine also activates mutant p53 function in tumor cells expressing endogenous 194F, 233L, 241F, and 273C mutants. Treatment with ellipticine alters mutant p53 reactivity to conformation-sensitive Pab1620 and Pab240 antibodies and increases its sequence-specific DNA-binding activity in vivo. Finally, ellipticine activates mutant p53 and induces p21
WAF1 and MDM2 expression in nude mouse tumor xenografts. These results demonstrate that ellipticine can restore transcription function to mutant p53. This property may contribute to the selectivity of ellipticine-derived compounds against tumor cell lines expressing mutant p53. Oncogene (2003 Oncogene ( ) 22, 4478-4487. doi:10.1038 Keywords: p53; ellipticine; rescue; conformation; mutant The p53 tumor-suppressor protein is regulated by a variety of stress signals and functions as a transcription factor to induce growth arrest or apoptosis of damaged or malignant cells. Approximately 55% of human tumors have genetically identifiable loss of p53 function, mainly by point mutations in the core (DNA-binding) domain (Hollstein et al., 1994) . The mutations found in human tumors can be classified into two classes. The 'contact' mutants affect the residues that are directly involved in contacting DNA (e.g., 248W, 273 H). The 'conformation' mutants affect residues that are important for maintaining the structural stability of the core domain (e.g., 175 H, 249S, 281G). Conformation mutants are thought to cause partial unfolding or misfolding of the core domain, resulting in increased sensitivity to in vitro protease digestion and exposure of the Pab240 antibody epitope that is normally packed in the hydrophobic core (Bargonetti et al., 1993; Cho et al., 1994) .
The majority of residues in the p53 core domain are targets of mutation in tumors, suggesting that the core domain is relatively unstable and point mutations in many different sites can cause significant functional disruption. The major consequence of core mutations is loss of sequence-specific DNA binding to the canonical p53-binding site at the physiological temperature. Mutant p53 also loses the ability to induce cell cycle arrest or apoptosis. Some of the mutants are temperature-sensitive and can be activated for DNA binding at subphysiological temperatures (201C) (Bargonetti et al., 1993) . A small subset of mutants such as 143A and 138 V are inactive at 371C, but can be activated at 321C to induce G1 arrest or apoptosis (Zhang et al., 1994; Pochampally et al., 1999) . Therefore, p53 mutations cause destabilization and partial unfolding of the core domain to different degrees depending on the position and nature of each mutation.
In unstressed normal cells, wildtype p53 is present at very low levels due to rapid degradation through the ubiquitin-dependent proteasome pathway. A major regulator of p53 turnover is the MDM2 oncoprotein. MDM2 binds to p53 and promotes its ubiquitination by acting as a ubiquitin E3 ligase (Haupt et al., 1997; Honda et al., 1997; Kubbutat et al., 1997) . MDM2 expression is also induced by p53 through a binding site in intron 1 of the MDM2 gene (Barak et al., 1993; Wu et al., 1993) , thus forming a negative feedback loop. A hallmark of tumors with mutant p53 is the accumulation of p53 to high levels (Soong et al., 1996) . Loss of the ability to activate MDM2 expression and binding to molecular chaperon hsp90 are thought to be responsible for the enhanced stability (Midgley and Lane, 1997; Peng et al., 2001) .
Since the majority of tumors with p53 mutations overexpress mutant p53, it is an attractive target for functional rescue. The feasibility of restoring mutant p53 function has been demonstrated by the use of Pab421 antibody and a C-terminal basic peptide of p53 to activate several mutants (Abarzua et al., 1995 (Abarzua et al., , 1996 Selivanova et al., 1997) . Second-site suppressor mutants have also been identified by genetic screen or directed mutagenesis that restores mutant p53 activity (Wieczorek et al., 1996; Brachmann et al., 1998) . Osmolytes such as glycerol (0.6 m) and trimethylamine N-oxide (75 mm) can restore the function of mutant p53 by acting as chemical chaperones to enhance protein stability (Brown et al., 1997; Ohnishi et al., 1999) . Recently, small molecules that can restore the function of mutant p53 at micromolar concentrations have been found by large-scale screening of compound libraries (Foster et al., 1999; Bykov et al., 2002) . Although the precise mechanisms of rescue by these compounds are still not clear, their ability to prevent wildtype p53 thermodenaturation in cell-free conditions suggest that they may rescue mutant p53 by directly interacting with the molecule and promoting its folding into wildtype-like conformation.
An analysis by Shi et al. (1998) of drug sensitivity profiles of the NCI 60 tumor cell line panel showed that many derivatives of the ellipticine alkaloid are more effective against cells with mutant p53. Additionally, Sugikawa et al. (1999) showed that 9-hydroxyellipticine stimulates p21WAF1 and Bax expression and G1 arrest in a mutant p53-dependent fashion. These observations suggested that ellipticine-like compounds may have the ability to restore mutant p53 transcription function. Therefore, we examined whether the prototype compound ellipticine has the ability to rescue mutant p53 activity. Using several approaches, we show that ellipticine and several of its derivatives can activate the transcription function of mutant p53.
Materials and methods

Cell lines and plasmids
MCF-7 (breast carcinoma, wt p53), HCT116 (colon carcinoma, wildtype p53), C33A (HPV-negative cervical carcinoma, p53 273c ), and DLD-1 (colon carcinoma, p53
241F
) were obtained from the ATCC. H1299 (lung carcinoma, p53-null) and Saos2 (osteosarcoma, p53-null) were provided by Dr Arnold J Levine. T47D (breast carcinoma, p53 , and p73a 156L mutants were described previously (Pochampally et al., 1999 (Pochampally et al., , 2000 . All cell lines were cultured in DMEM medium with high glutamine (Gibco) and supplemented with nonessential amino acids. The p53-responsive luciferase reporter pBP100-GL2 contains the p53-binding site from intron 1 of MDM2 gene (Freedman et al., 1997) .
Compounds and treatment
CP31398 was kindly provided by Dr Farzan Rastinejad (Pfizer Central Research), dissolved in DMSO, stored at À801C, and used at 10-15 mg/ml. Ellipticine (NSC 71795) was obtained from the NCI Drug Discovery Program or from Sigma, dissolved in 1% acetic acid, and stored at À801C. Ellipticine derivatives (NSC 98949, 100594, 125630, 125631, 162907, 176327, 176328, 237068, 338258, 359449, 604574, 657149) were provided by Dr Robert Schultz (NCI). For injection of mice, athymic nude mice (6-week old, NCI-Federic) were injected with 10 7 DLD1 or C33A cells subcutaneously on the dorsal flank. After 20 days, mice bearing tumors of B1 g were used. Ellipticine (Sigma) was dissolved in 1% acetic acid and neutralized to pH 7.0 with NaOH. NaCl was then added to 150 mm. Each mouse was given 0.1 ml of ellipticine solution at a dose of 30-90 mg/kg by intraperitoneal injection every 24 h. Tumor samples were collected 24-72 h after injection. Cell viability was determined using the CellTiter 96 kit (Promega).
Western blot and immunoprecipitation
Cells were lysed in RIPA buffer (1% sodium deoxycholate, 0.1% SDS, 1% Triton X-100, 50 mm Tris pH 7.4, 150 mm NaCl, 1 mm PMSF), 100-200 mg protein was fractionated by SDS-PAGE and transferred to Immobilon P filters (Millipore). The filter was blocked for 1 h with PBS containing 5% nonfat dry milk, 0.1% Tween-20 and then incubated for 1 h with 3G9 (MDM2) or DO-1 (p53, Pharmingen) in PBS containing 5% nonfat dry milk. Bound primary antibody was detected by incubating for 1 h with HRP-goat-anti-mouse IgG or HRP-protein A. The filter was developed using the ECLplus reagent (Amersham). For immunoprecipitation (IP)-Western blot analysis, tumor tissue was homogenized in lysis buffer (50 mm Tris-HCl (pH 8.0), 5 mm EDTA, 150 mm NaCl, 0.5% NP40, 1 mm PMSF), 1000 mg protein was precleared with protein A-Sepharose beads (Sigma) and immunoprecipitated with MDM2 antibody for 4 h at 41C. The beads were washed with lysis buffer and the immunoprecipitate was fractionated by SDS-PAGE, followed by Western blot for MDM2.
Immunofluorescence staining
Cells cultured on chamber slides were fixed with acetonemethanol (1 : 1) for 3 min at room temperature, blocked with PBS þ 10% normal goat serum (NGS) for 20 min, and incubated with anti-p53 Pab1801 hybridoma supernatant (1 : 10 dilution) or anti-MDM2 2A9 hybridoma supernatant (1/100 dilution) in PBS þ 10% NGS for 2 h. The slides were washed with PBS þ 0.1% Triton X-100, incubated with FITCgoat-anti-mouse IgG in PBS þ 10% NGS for 1 h, washed with PBS þ 0.1% Triton X-100 and mounted.
Chromatin IP and quantitative PCR
Chromatin IP was carried out using published procedures (Boyd et al., 1998) . P53 IP was performed using DO-1 antibody. Co-precipitated DNA was analysed by real-time PCR for the presence of p53-binding element from MDM2 intron 1 using the following primers and probe: Human MDM2 forward primer: 5 0 GTGGCGATTGGAGGGTA GAC; human MDM2 reverse primer: 5 0 GTCGGTGCTTA CCTGGATCAG; human MDM2 probe 6FAM-CACG-GACGCACGCC-MGBNFQ (Applied Biosystems). Nonspecific co-precipitation of the GAPDH promoter was determined by the following primers and probe: GAPDH forward primer: 5 0 -GTATTCCCCCAGGTTTACAT; GAPDH reverse primer: 5 0 -TTCTGTCTTCCACTCACTCC; GAPDH probe: 6FAM-GGCTGAGAACGGGAAG-MGBNFQ. Real-time PCR analysis was carried out by the Molecular Biology Core of H Lee Moffitt Cancer Center.
ELISA assay
Purified p53 monoclonal antibodies DO-1, Pab1620, and Pab240 (50 ml at 5 mg/ml in PBS) were used to coat each well in 96-well ELISA plates. The plates were then blocked for 8 h at 41C with blocking buffer (PBS with 0.05% Tween-20 and 0.25% BSA). Cells were lysed in lysis buffer (50 mm Tris-HCl (pH 8.0), 5 mm EDTA, 150 mm NaCl, 0.5% NP40, 1 mm PMSF) and 50 ml lysate (20 mg/ml cellular protein) was incubated with each coated well for 16 h at 41C. After washing with room temperature de-ionized water, bound p53 was detected by incubation with rabbit-anti-p53 polyclonal antibody FL393 (Santa Cruz Biotechnology) and then with HRP-conjugated swine-anti-rabbit Ig for 2 h each at 41C. HRP activity was detected by incubation with the TMB substrate (KPL). For in vitro denaturation assay, purified His6-p53 (kindly provided by Dr Hua Lu) was diluted to 1 mg/ml in lysis buffer and incubated at 431C in the absence or presence of drugs. Samples were retrieved at indicated time points and kept at 41C for ELISA analysis, as described above.
Results
Ellipticine restores mutant p53 transcription function
To test whether ellipticine can restore mutant p53 transcriptional activity, Saos2 cells (a p53-null osteosarcoma cell line) were stably transfected with mutant p53 expression vectors and the p53-responsive BP100-luciferase reporter (Freedman et al., 1997) . Cells were treated with ellipticine for 16 hours and p53 transcription function was measured by luciferase assay. The results showed that ellipticine induced the transcriptional function of p53 hot spot mutant 175 H, 248W, 249S, 273 H, and 281G by 5-6-fold ( Figure 1a and data not shown). The ability of ellipticine to induce the p53-responsive reporter was dependent on the presence of mutant p53, since the reporter was not activated by the drug when transfected alone ( Figure 1a ). The effect of ellipticine was highly dose-dependent, with optimal concentration at B8 mm. Higher concentrations resulted in loss of luciferase activity below basal level, which may be caused by inhibition of transcription in general. A similar effect of ellipticine was also observed in H1299 cells (a p53-null lung carcinoma cell line) transfected with mutant p53 (data not shown).
To further test the specificity of ellipticine, p53-null H1299 cells transfected with a temperature-sensitive p53 138 V mutant was used (Pochampally et al., 1999) . The H1299-p53 138 V cells were transfected with the BP100-luciferase reporter. The p53 138 V mutant is transcriptionally active at 321C and inactive at 37-391C due to a switch to mutant conformation. We found that treatment with 6-8 mm ellipticine for 8 h at 391C induced strong BP100-luciferase expression to levels similar to activation at 321C (Figure 1b) . As a positive control, the CP31398 compound also activated BP100-luciferase expression as expected from its ability to restore mutant p53 function (Foster et al., 1999) . Ellipticine treatment had no obvious effect on p53
138 V activity at 321C, which was already highly active ( Figure 1b) .
Next, H1299 cells stably transfected with temperature-sensitive mutants of p63 and p73 were also tested for activation by ellipticine. These mutants were created by mutating the residue corresponding to valine 138 of p53, resulting in temperature-sensitivity profiles similar to the p53 138 V mutant (Pochampally et al., 2000) . The results showed that temperature-sensitive p63g
167P and p73a 156L mutants were not activated by ellipticine at 391C (Figure 1c and data not shown) . Therefore, ellipticine specifically activates the transcription function of mutant p53 but not other p53 homologs. Control experiments also revealed that ellipticine activated wildtype p53 in MCF7 (data not shown), consistent with its ability to induce DNA damage by inhibition of topoisomerase 2. However, another topoisomerase 2 inhibitor, etoposide, did not activate mutant p53, and the topoisomerase 1 inhibitor camptothecin activated wildtype p53 in MCF7 cells but not mutant p53 (data not shown), suggesting that mutant p53 rescue is a distinct function of ellipticine.
Induction of endogenous p53-responsive genes by ellipticine
To determine whether ellipticine-activated mutant p53 induce endogenous p53-responsive genes, MDM2 and p21WAF1 expression were analysed. Treatment of H1299 cells with ellipticine did not induce expression of MDM2 and p21. However, in mutant p53-transfected H1299 cells, strong induction of both genes was observed by Western blot (Figure 2a ). This result suggested that ellipticine induced MDM2 and p21 expression by restoration of mutant p53 transcription function. Ellipticine also induced expression of MDM2 and p21 in several tumor cell lines (C33A, T47D, DU145) with endogenous mutant p53 (Figure 2a and data not shown).
To determine the efficiency of p53 activation by ellipticine, MDM2 expression was examined by immunofluorescence staining. Ellipticine treatment of T47D cells induced strong staining of MDM2 in nearly 100% of the nuclei (Figure 2b ). Consistent with luciferase assay results, ellipticine also induced p53 and MDM2 levels in the wildtype p53 cell line MCF7 (data not shown). Interestingly, in each cell line expressing endogenous or transfected mutant p53, MDM2 induced by ellipticine invariably accumulate in the nucleolus (Figure 2b and data not shown). This may be due to the presence of ARF in these cells, which targets MDM2 to the nucleolus. The localization and level of mutant p53 did not change after ellipticine treatment, maintaining a diffused nuclear distribution (Figure 2b ).
Ellipticine alters mutant p53 conformation
Mutant p53 has altered conformation that can be detected by immunoprecipitation using Pab1620 and Pab240 antibodies (Gannon et al., 1990; Vojtesek et al., 1995) . Pab1620 reactivity is often associated with wildtype p53 conformation, although it is not always equal to functionally active p53. Pab240 reactivity is an indicator of denatured p53 because it is associated with recognition of an internal epitope in the core domain. We tested whether ellipticine can induce changes in p53 conformation as determined by Pab1620/Pab240 reactivity.
We established an ELISA assay using plates coated with Pab1620, Pab240, and DO-1 antibodies. Lysates from DLD1 cells treated with ellipticine were incubated with plates coated with the antibodies and the captured p53 was detected by rabbit anti-p53 polyclonal antibody. The results showed that ellipticine treatment induced a dose-dependent increase of Pab1620 reactivity and corresponding reduction of Pab240 reactivity (B30%). The reactivity to conformation-independent DO-1 was not affected (Figure 3a ). Since ellipticine is also an inhibitor of topoisomerase 2, we tested whether another topoisomerase 2 inhibitor etoposide had a similar effect. Treatment with etoposide did not change the conformation of mutant p53 in this assay (data not shown). Therefore, ellipticine induced a shift of mutant p53 conformation towards wildtype. This activity was not due to its ability to inhibit topoisomerase 2.
To determine whether rescue of mutant p53 conformation in vivo by ellipticine required new protein synthesis, ellipticine treatment was also performed in the presence of cyclohexamide to inhibit protein synthesis. The result showed that cyclohexamide blocked rescue of mutant p53 conformation (Figure 3b ), suggesting that ellipticine only rescues newly synthesized mutant p53. Alternatively, expression of other proteins may also be required for mutant p53 rescue.
Two previously described mutant p53-activating compounds can inhibit heat denaturation of wildtype p53 in vitro (Foster et al., 1999; Bykov et al., 2002) , presumably by interacting with p53 and stabilizing its structure at high temperature. To determine whether 138 V mutant at 391C by ellipticine and CP31398.
H1299 cells stably transfected with p53
138 V and BP100-luc were cultured at 391C (nonpermissive temperature) or 321C (permissive temperature) in the presence of drugs (8 mm ellipticine, 16 mg/ml CP31398) for 8 h and analysed for luciferase expression. (c) Temperature-sensitive p73a 156L was not activated by ellipticine or CP31398. The assay was performed identical to (b) Activation of mutant p53 by ellipticine Y Peng et al ellipticine can prevent wildtype p53 denaturation in vitro, purified His6-p53 (wildtype) was incubated at 431C in the presence or absence of ellipticine and change of Pab1620/Pab240 reactivity measured. The result showed that unlike the CP31398 compound, ellipticine (5-20 mm) did not prevent wildtype p53 thermo denaturation in vitro (Figure 3c ). Therefore, ellipticine may use a different mechanism to rescue mutant p53 conformation. It remains to be determined whether ellipticine rescues mutant p53 activity by direct binding to p53.
Ellipticine enhances sequence-specific DNA binding by mutant p53
To confirm that activation of p53-responsive genes after ellipticine treatment was due to sequence-specific DNA binding by mutant p53, we examined in vivo DNA binding using chromatin IP (CHIP). Saos2 cells stably transfected with p53 175 H were crosslinked by formaldehyde and p53 was precipitated by DO-1 antibody. The amount of co-precipitated p53-binding element in MDM2 intron 1 was determined by quantitative realtime PCR. The result showed that treatment with ellipticine for 16 h resulted in fourfold induction of DNA binding in Saos2 cells expressing mutant p53, but not in control Saos2 without p53 (Figure 4a ). The increase of p53 DNA binding in this cell line was consistent with the level of luciferase induction in reporter assay using Saos2-175H-BP100-luc cells (Figure 1) . Treatment of DLD1 cells expressing endogenous mutant p53 also showed a threefold increase of p53 DNA-binding activity after ellipticine treatment (Figure 4b) . Therefore, ellipticine can partially restore the sequence-specific DNA-binding function of mutant p53 in vivo.
Induction of mutant p53-dependent apoptosis by ellipticine
To determine the biological effects of mutant p53 activation, pooled H1299-273 H stable colonies (490% cells positive for mutant p53 by IF staining) were treated with ellipticine for 24 h and analysed by FACS. The results showed that control H1299 cells treated with ellipticine accumulated in the G2/ M phase, indicating that the drug induced G2/M arrest independent of p53 ( Figure 5a ). This may be due to its ability to inhibit topoisomerase 2 (Froelich-Ammon et al., 1995). H1299-273 H cells showed significant cell death after ellipticine treatment (Figure 5a ) that appeared as sub-2N population on FACS analysis, suggesting that activation of mutant p53 resulted in apoptosis. When cell viability was determined using the MTS assay which measures mitochondria metabolic activity, there was also significant cell death after 24 h treatment of H1299-273 H cells with ellipticine ( Figure 5b ). In long-term treatments, control H1299 cells were also killed by ellipticine (not shown), most likely due to other cytotoxic activities of ellipticine, such as topoisomerase 2 inhibition and DNA intercalation. Therefore, expression of mutant p53 led to higher sensitivity to short-term ellipticine treatment. A similar experiment using H1299-175 H cells resulted in moderate G1 arrest, but no increase in apoptosis after ellipticine treatment (data not shown), suggesting that the biological outcome may be allele-dependent due to different efficiency of rescue and the conformation of different mutants.
Activation of mutant p53 in tumor xenografts
To test whether ellipticine activates mutant p53 in tumors in vivo, we generated tumor xenografts in athymic nude mice using DLD1 and C33A cells. Cells were inoculated into nude mice by subcutaneous injection and allowed to develop into B1 cm 3 tumor nodules at the injection site. The mice were then treated with ellipticine at 30, 60, and 90 mg/kg by IP injection. Tumors were harvested 24-72 h after injection and MDM2 expression levels were determined by immunoprecipitation followed by Western blot. The results showed that MDM2 expression was significantly in- (Figure 6 ). Furthermore, p21 expression was also induced in ellipticinetreated C33A tumor samples (Figure 6 ). This result suggested that ellipticine was able to activate the endogenous mutant p53 in tumors in vivo.
Activation of mutant p53 by ellipticine derivatives
Previous tests conducted by the NCI of over 100 ellipticine derivatives in short-term growth inhibition/ cell death assay using 60 tumor cell lines revealed that many of these compounds showed a degree of selective (Shi et al., 1998) . To determine whether these compounds also activate mutant p53, we tested 12 ellipticine derivatives provided by the NCI drug-discovery program using Saos2 cells stably transfected with p53 175 H and BP100-luciferase. The results showed that six (50%) of these compounds activated p53
175 H from 2-6-fold ( Figure 7 ). Therefore, it appears that the ability to activate mutant p53 is retained by many of the ellipticine derivatives. This function may be responsible or contribute to their selectivity against tumor cell lines expressing mutant p53.
Discussion
The results presented above show that ellipticine can restore the sequence-specific DNA binding and transcription function of several p53 point mutants of either the 'conformation' or 'contact' type. Ellipticine is likely to act by inducing the correct folding of mutant p53 in vivo. Treatment with ellipticine induced moderate changes in mutant p53 reactivities to conformational antibodies Pab1620 and Pab240. The results are consistent with conversion of p53 conformation from mutant towards wildtype through a mechanism that requires new protein synthesis. Ellipticine also induced expression of p53-responsive genes p21 and MDM2 in a mutant p53-dependent fashion, demonstrating that it activates these genes by restoring mutant p53 transcriptional activity.
Unlike CP31398, which can prevent wildtype p53 conformational change after heat treatment, ellipticine does not prevent thermodenaturation of p53 in vitro. Therefore, it remains to be determined whether ellipticine acts by direct binding to mutant p53 and stabilizing its DNA-binding conformation. It is possible that the compound interacts with mutant p53 in vivo and facilitates its correct folding with the help of other cellular proteins such as molecular chaperones. Inhibition of protein synthesis blocked the ability of ellipticine to alter the antibody reactivity of mutant p53, suggesting that it may only rescue the folding of newly synthesized p53. Alternatively, ellipticine may modulate expression of other proteins required for mutant p53 rescue. Ellipticine may also need to be metabolized in vivo before gaining the ability to rescue mutant p53, which may account for its failure to block p53 denaturation in vitro.
Ellipticine is an inhibitor of several cellular enzymes such as CDK, topoisomerase 2, and casein kinase II. Therefore, it is possible that ellipticine-like compounds induce mutant p53 conformational change by altering its phosphorylation. If this is the case, identifying the target kinase may facilitate development of more specific inhibitors that activate mutant p53. Additionally, identifying the change in phosphorylation that results in mutant p53 activation will help to understand the structural basis of activation and possibly design of specific molecules that can perform this function. Use of phosphorylation-specific antibodies has revealed that serine 15 phosphorylation of mutant p53 was significantly enhanced by ellipticine (our unpublished observation). Since other DNA-damage drugs also induce phosphorylation of serine 15 but fail to activate mutant p53, this modification alone is unlikely to be responsible for mutant p53 conformational rescue by ellipticine, but may contribute to the transcription function of rescued p53.
Since ellipticine is also a DNA-intercalating agent, it may act by binding DNA and stabilizing the mutant p53-DNA complex. However, the fact that mutant p53 from ellipticine-treated cells maintains altered reactivity to antibodies in ELISA assay in the absence of the drug suggests that its conformation is changed after treatment and this change may be sufficient to confer DNAbinding and transcription activity. Furthermore, during the course of our experiments, a report by Sugikawa et al. (2002) also showed that mutant p53 in nuclear extract from 9-hydroxyellipticine-treated cells regained DNA gel shift activity. Since the DNA-binding assay was also performed in the absence of drug, it suggests that mutant p53 from the treated cells is capable of binding to DNA without additional DNA-drug interaction.
The ability of ellipticine to restore mutant p53 function suggests that other compounds in this family may also have similar functions. A recent analysis of the NCI 60 tumor cell line screen showed that ellipticine-like compounds are more potent against cell lines that harbor mutant p53 in short-term growth inhibition assays (Shi et al., 1998) . Our results show that many ellipticine derivatives have the ability to activate mutant p53, suggesting that this function may in part account for their selective toxicity against tumor cells with mutant p53. Further study of other ellipticine derivatives may lead to more efficient compounds that can achieve mutant p53 rescue and specific targeting of tumors with mutant p53. Since ellipticine appears to activate mutant p53 through a different mechanism than CP31398, it also provides an additional tool to study the molecular mechanisms that can restore mutant p53 activity.
Since its isolation from the plant Ochrosia elliptica in 1959, a large number of ellipticine derivatives have been synthesized and tested for antitumor activity in preclinical models. Ellipticine derivatives, 2-methyl-9-hydroxyellipticinium and retelliptine dihydrochloride, were tested in Phase I clinical trials (Gouyette et al., 1982; Kattan et al., 1994) . Elliptinium acetate was tested in Phase II clinical trials and showed moderate antitumor activity in patients with metastatic breast cancer (Buzdar et al., 1990; Rouesse et al., 1993) . The utility of these drugs was limited by toxicities such as nausea, hypertension, muscular cramp, EKG anomalies, xerostomia, and hemolytic reactions. Selection of compounds for these early clinical studies was based on general cytotoxicities against tumor cells without knowledge of p53 status and the compound's ability to rescue mutant p53. Our results suggest that the effectiveness of ellipticine derivatives may be improved if their mechanism of action is understood and more specific compounds are identified based on its effect on mutant p53. Furthermore, clinical trials with ellipticine derivatives should take into consideration the tumor p53 mutation status.
